Scilex Holding Company announces major pharmacy initiative with the national leading pharmacy chain to stock ELYXYB® in most of their stores throughout the U.S.
PALO ALTO, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq:SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced a national leading pharmacy chain to stock ELYXYB®. Previously, Scilex Holding Company announced pharmacy initiative to stock ELYXYB® for the other leading pharmacy chain in the U.S. Scilex is also in the process of negotiating similar potential stocking arrangements with additional pharmacy chains in the U.S.
Related news for (SCLX)
- Proof of Human, Promise of Profit
- MoBot’s Stock Market Highlights – 03/03/25 04:00 PM
- Today’s Top Performers: MoBot’s Market Review 03/03/25 03:00 PM
- Denali Capital Acquisition Corp and Scilex Holding’s Semnur Pharmaceuticals Sign LOI for Proposed Business Combination
- Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024